Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering May 16, 2023
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update May 12, 2023
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update May 5, 2023
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference Apr 19, 2023
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference Apr 11, 2023
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Mar 16, 2023
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update Mar 6, 2023
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update Nov 14, 2022
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update Nov 1, 2022
